Admescope offers a comprehensive portfolio of ADME-Tox services to support your drug discovery and development program — from early screening to IND-enabling studies. Our team works with all major drug modalities, including small molecules, peptides, oligonucleotides, and antibody-drug conjugates, applying state-of-the-art instrumentation and deep scientific expertise to deliver reliable, project-specific data.
In Vitro Metabolism
Evaluate the metabolic fate of your compound in the liver and in extrahepatic tissues. Our services cover metabolic stability using hepatocytes, liver microsomes, and recombinant enzymes, along with metabolite identification and profiling, enzyme phenotyping across CYP, UGT, SULT, FMO, and other pathways, and metabolic soft spot analysis.
Safety Metabolism
Characterize human and disproportionate metabolites using both in vitro and in vivo methods to support regulatory safety assessments. Services include cross-species metabolite profiling, MIST analysis, and radiolabeled ADME studies aligned with ICH M3(R2) and FDA guidance.
In Vivo DMPK
Generate pharmacokinetic data in mouse and rat to characterize absorption, distribution, metabolism, and excretion in vivo. Studies can be run as standalone packages or combined with in vitro data to build a full ADME profile for lead optimization and IND-enabling programs.
Drug Interactions
Assess drug-drug interaction (DDI) risk through CYP and UGT inhibition and induction studies, enzyme phenotyping, and a full transporter panel covering MDR1, BCRP, OATPs, OATs, OCTs, and MATEs — designed in line with FDA, EMA, and ICH M12 guidance.
Quantitative Bioanalysis
Comprehensive bioanalytical support for small molecules, peptides, oligonucleotides, antibodies, and ADCs using LC-MS/MS, LC-HR/MS, ELISA, and qPCR. We offer method development and validation, standalone sample analysis for customer-supplied matrices, and full bioanalytical support within DMPK packages.
Permeability and Transporters
Evaluate compound absorption and transport using PAMPA, Caco-2, and MDCK assays alongside a comprehensive transporter panel for both substrate and inhibition potential. Caco-2 permeability studies are fully aligned with ICH M9 guidance, supporting BCS classification and biowaiver applications.
Physicochemistry and Binding
Characterize the physicochemical properties that govern compound distribution and target interaction. Services include solubility, lipophilicity (logP/D, ElogD), plasma protein binding, blood-to-plasma ratio, and tissue and microsome binding — key inputs for PBPK modeling and cross-species scaling.
In Vitro Toxicology
Identify safety liabilities early with a broad in vitro toxicology panel. Our DILIscope package covers drug-induced liver injury using primary human hepatocytes and high-content imaging. Additional assays include genotoxicity, cytotoxicity, hERG cardiotoxicity, and mechanistic tox assays targeting oxidative stress, apoptosis, and mitochondrial dysfunction.
Biologics ADME-Tox
Specialized ADME-Tox services for complex modalities including peptides, monoclonal antibodies, proteins, oligonucleotides, and ADCs. Services include in vivo PK studies, ADC payload metabolite identification, protein quantification by LC-MS and ELISA, structural characterization, and biomolecular interaction analysis via SPR and BLI.
Early ADME Screening
Accelerate lead optimization with automated early ADME screening, delivering results within one week for routine assays. The panel covers solubility, logD, metabolic stability, plasma protein binding, CYP inhibition, and permeability — as standalone assays or integrated into broader Symeres drug discovery programs.
Custom Services
Have a study requirement that falls outside our standard portfolio? We design custom protocols tailored to your specific compound, matrix, or project needs.
Why Admescope?
As part of the Symeres group, Admescope combines the flexibility and responsiveness of a specialist CRO with access to broader drug discovery and medicinal chemistry capabilities. Our AAALAC-accredited in vivo facility, experienced scientific team, and modern analytical infrastructure — including multiple LC-MS/MS and LC-HR/MS platforms — ensure the data quality your program depends on.
Frequently Asked Questions
Admescope works with small molecules, peptides, oligonucleotides, monoclonal antibodies, proteins, and antibody-drug conjugates (ADCs). Most assays can be adapted to the specific analytical and experimental requirements of each modality.
Yes. While most work is conducted on a non-GLP basis, Admescope designs study packages aligned with regulatory expectations from the FDA and EMA and has extensive experience supporting both early and late preclinical programmes.
Turnaround times depend on the assay and study scope. Routine early ADME assay results are typically delivered within one week. For more complex programmes, such as in vivo DMPK or metabolite identification studies, timelines are agreed during project setup.
Yes. Admescope offers standalone bioanalytical support for customer-supplied in vitro and in vivo samples and can assist with import logistics for biological materials and matrices from regulated species.
Yes. In addition to individual assays, Admescope offers tailored packages such as the Early ADME screening panel and the DILIscope hepatotoxicity package. Custom programmes combining multiple service areas can also be developed around the specific requirements of your project.
